A nurse is caring for a 1-month-old infant who weighs 3500 g and is prescribed a dose of cephazolin 50 mg/kg by intermittent IV bolus three times daily. How many mg should the nurse administer per dose? (Round the answer to the nearest tenth. Use a leading zero if it applies. Do not use a trailing zero)

A. "I will feel less hungry during meals while I am taking orlistat": Orlistat works by blocking the absorption of dietary fat in the intestines rather than suppressing appetite. Therefore, it does not typically reduce hunger during meals.
B. "I will eat a no-fat diet to prevent side effects from the medication": Orlistat can cause gastrointestinal side effects such as oily stools, fecal incontinence, and flatulence, particularly when consumed with high-fat meals. While reducing fat intake can help minimize these side effects, it is not necessary to eliminate fat entirely from the diet. The statement is partially correct but not the best response indicating full understanding.
C. "I will stop taking orlistat and call my doctor if my urine gets darker in color": Dark urine can indicate liver problems, which are a potential side effect of orlistat. Therefore, it is crucial for the client to monitor for this symptom and contact their healthcare provider if it occurs. This response indicates that the client understands the potential adverse effects of the medication.
D. "I will take my dose of orlistat every morning an hour before breakfast": Orlistat is typically taken with meals or up to one hour after eating. Taking it on an empty stomach before breakfast is not recommended.

A. Bleeding: While haloperidol can rarely cause agranulocytosis, which may lead to bleeding, it is not a common adverse effect associated with the medication. However, clients taking antipsychotic medications like haloperidol should be monitored for any signs of bleeding, such as petechiae or bruising.
B. Cataracts: Haloperidol is not typically associated with the development of cataracts. However, long-term use of certain antipsychotic medications, including haloperidol, may increase the risk of developing metabolic side effects such as weight gain and dyslipidemia, which could indirectly contribute to the risk of cataract formation.
C. Dysrhythmias: This is the correct answer. Haloperidol has the potential to prolong the QT interval, leading to a type of dysrhythmia known as torsade’s de pointes. Therefore, clients taking haloperidol should be monitored for signs of QT prolongation, such as palpitations, syncope, or sudden cardiac arrest.
D. Pancreatitis: While rare, haloperidol has been associated with pancreatitis as a potential adverse effect. However, dysrhythmias are a more common and immediate concern, especially with acute administration or in clients with predisposing factors for QT prolongation, such as electrolyte imbalances or concurrent use of other medications known to prolong the QT interval.